(Q51308310)

3 April 2018

title

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. (English)

1 reference

3 April 2018

11

E Braunwald

1 reference

3 April 2018

G Leibowitz

1

1 reference

3 April 2018

A Cahn

2

1 reference

3 April 2018

D L Bhatt

3

1 reference

3 April 2018

B Hirshberg

4

1 reference

3 April 2018

O Mosenzon

5

1 reference

3 April 2018

C Wei

6

1 reference

3 April 2018

G Jermendy

7

1 reference

3 April 2018

W H-H Sheu

8

1 reference

3 April 2018

J L Sendon

9

1 reference

3 April 2018

K Im

10

1 reference

3 April 2018

B M Scirica

12

1 reference

3 April 2018

I Raz

13

1 reference

3 April 2018

publication date

25 February 2015

1 reference

3 April 2018

Diabetes, Obesity and Metabolism

published in

1 reference

3 April 2018

volume

17

1 reference

3 April 2018

issue

5

1 reference

3 April 2018

page(s)

487-494

1 reference

3 April 2018

Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.

cites work

1 reference

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

Deteriorating beta-cell function in type 2 diabetes: a long-term model

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes.

21 January 2018

1 reference

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

21 January 2018

1 reference

Clinical and genetic determinants of progression of type 2 diabetes: a DIRECT study

21 January 2018

1 reference

Changes in treatment after the start of oral hypoglycaemic therapy in Type 2 diabetes: a population-based study

21 January 2018

1 reference

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes

21 January 2018

1 reference

Pharmacology, physiology, and mechanisms of incretin hormone action

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

21 January 2018

1 reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study

21 January 2018

1 reference

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial

21 January 2018

1 reference

Use and abuse of HOMA modeling

21 January 2018

1 reference

Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials

21 January 2018

1 reference

Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria

21 January 2018

1 reference

The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.

21 January 2018

1 reference

Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation

21 January 2018

1 reference

Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: a long-term follow-up study.

21 January 2018

1 reference

Cigarette smoking, oral moist snuff use and glucose intolerance.

21 January 2018

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12445

1 reference

3 April 2018

PubMed ID

25656169

1 reference

3 April 2018